Pharmaceutical companies will lose more than £40bn by 2019, due to patents on drugs expiring.
Related Article: Nearly twice as many patients in deprived areas prescribed dependency-forming meds
It is claimed companies such as Otsuka, Eli Lilly and AstraZeneca (AZ) will be affected the most, especially in the central nervous system (CNS) medication sector.
GlobalData analyst for healthcare industry dynamics, Adam Dion, said: “AZ’s CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel, a treatment for bipolar disorder, allowing for cheaper generic alternatives.”
Related Article: Finding sustainable funding solution is ‘matter of urgency’ for government
It is claimed AZ’s shares fell to 3% in 2013 from 9% in 2010.
Dion said Eli Lilly’s market share declined from 14.3% in 2010 to 11.2% in 2013, due to decreasing sales of the company’s medication for schizophrenia and bipolar disorder.
Related Article: NICE recommends ‘game changer’ wearable tech for type 1 diabetes
It is claimed Ablify, an anti-psychotic drug, produced by Otsuka, will have its US patent expire in 2015, meaning the drug is predicted to lose nearly £5bn by 2019 as a result of generic medications.
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.